Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxic-ischemic injury.
OBJECTIVE
Brain injury from preterm birth predisposes children to cerebral palsy, epilepsy, cognitive delay, and behavioral abnormalities. The CNS injury often begins before the early birth, which hinders diagnosis and concurrent treatment. Safe, effective postnatal interventions are urgently needed to minimize these chronic neurological deficits. Erythropoietin (EPO) is a pleiotropic neuroprotective cytokine, but the biological basis of its efficacy in the damaged developing brain remains unclear. Coordinated expression of EPO ligand and receptor expression occurs during CNS development to promote neural cell survival. The authors propose that prenatal third trimester global hypoxia-ischemia disrupts the developmentally regulated expression of neural cell EPO signaling, and predisposes neural cells to death. Furthermore, the authors suggest that neonatal exogenous recombinant human EPO (rhEPO) administration can restore the mismatch of EPO ligand and receptor levels, and enhance neural cell survival.


METHODS
Transient systemic hypoxia-ischemia (TSHI) on embryonic Day 18 in rats mimics human early-third trimester placental insufficiency. This model was used to test the authors' hypothesis using a novel clinically relevant paradigm of prenatal injury on embryonic Day 18, neonatal systemic rhEPO administration initiated 4 days after injury on postnatal Day 1, and histological, biochemical, and functional analyses in neonatal, juvenile, and adult rats.


RESULTS
The results showed that prenatal TSHI upregulates brain EPO receptors, but not EPO ligand. Sustained EPO receptor upregulation was pronounced on oligodendroglial lineage cells and neurons, neural cell populations particularly prone to loss from CNS injury due to preterm birth. Postnatal rhEPO administration after prenatal TSHI minimized histological damage and rescued oligodendrocytes and gamma-aminobutyric acidergic interneurons. Myelin basic protein expression in adult rats after insult was reduced compared with sham controls, but could be restored to near normal levels by neonatal rhEPO treatment. Erythropoietin-treated TSHI rats performed significantly better than their saline-treated peers as adults in motor skills tests, and showed significant seizure threshold restoration using a pentylenetetrazole increasing-dose paradigm.


CONCLUSIONS
These data demonstrate that neonatal rhEPO administration in a novel clinically relevant paradigm initiated 4 days after a global prenatal hypoxic-ischemic insult in rats rescues neural cells, and induces lasting histological and functional improvement in adult rats.
Mazur
Marcus
M
Department of Neurosurgery, Rainbow Babies & Children's Hospital, Center for Translational Neuroscience, The Neurological Institute of University Hospitals Case Medical Center, Case Western Reserve School of Medicine, Cleveland, Ohio 44106, USA.
Miller
Robert H
RH
Robinson
Shenandoah
S
D000818:Animals; D015153:Blotting, Western; D016923:Cell Death / Q000187:drug effects; D004921:Erythropoietin / Q000032:analysis / Q000494:pharmacology / Q000627:therapeutic use*; D005315:Fetal Diseases / Q000473:pathology* / Q000503:physiopathology; D020925:Hypoxia-Ischemia, Brain / Q000473:pathology* / Q000503:physiopathology; D007150:Immunohistochemistry; D008024:Ligands; D009048:Motor Skills; D009474:Neurons / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D009836:Oligodendroglia / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley; D017467:Receptors, Erythropoietin / Q000032:analysis; D011994:Recombinant Proteins; D012640:Seizures / Q000503:physiopathology
D008024:Ligands; D017467:Receptors, Erythropoietin; D011994:Recombinant Proteins; D004921:Erythropoietin
Lancet Neurol. 2009 Jan;8(1):110-24
19081519
Neurosci Lett. 2007 Oct 2;425(3):177-82
17825990
Eur J Clin Pharmacol. 2005 May;61(3):189-95
15776276
Physiology (Bethesda). 2008 Oct;23:263-74
18927202
Nat Neurosci. 2007 Apr;10(4):453-61
17351636
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10659-64
12130665
Neonatology. 2007;91(1):36-43
17344650
Natl Vital Stat Rep. 2007 Dec 5;56(6):1-103
18277471
Pediatr Res. 2007 Jun;61(6):671-5
17426655
Anat Embryol (Berl). 2005 Oct;210(3):209-19
16151855
Brain Res. 2005 May 31;1045(1-2):22-30
15910759
Neuroscience. 2007 Feb 9;144(3):865-77
17141961
Nature. 1996 May 30;381(6581):415-21
8632796
Pediatr Res. 2005 Aug;58(2):297-301
16055937
Life Sci. 2006 Apr 25;78(22):2571-6
16343549
J Neurosci. 2000 Nov 1;20(21):7994-8004
11050120
Neuropediatrics. 1999 Feb;30(1):14-8
10222455
Pediatr Res. 2005 Jul;58(1):106-11
15879287
Brain Dev. 2003 Oct;25(7):494-8
13129593
Epilepsy Behav. 2005 Nov;7(3):345-63
16061421
Pediatrics. 2008 Aug;122(2):383-91
18676557
J Neurosci Methods. 2002 Apr 15;115(2):169-79
11992668
Neurology. 2007 Nov 6;69(19):1816-22
17984448
Epilepsia. 2005 Oct;46(10):1599-602
16190930
Nature. 2001 Aug 9;412(6847):641-7
11493922
Neurobiol Dis. 2005 Apr;18(3):568-81
15755683
Pediatrics. 2005 Jul;116(1):221-5
15995055
Biol Neonate. 2003;83(3):224-8
12660442
J Cereb Blood Flow Metab. 2007 May;27(5):1043-54
17077815
Pediatrics. 2008 Aug;122(2):375-82
18676556
J Biol Chem. 2007 Aug 31;282(35):25875-83
17604282
Nucleic Acids Res. 2001 May 1;29(9):e45
11328886
Neonatology. 2008;94(4):255-66
18784421
Dev Neurosci. 2007;29(4-5):321-30
17762200
Dev Sci. 2006 Jul;9(4):338-49
16764607
Pediatrics. 2005 Apr;115(4):997-1003
15805376
Development. 2002 Jan;129(2):505-16
11807041
J Neurosurg. 2006 Jun;104(6 Suppl):396-408
16776375
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10526-31
10984541
J Biol Chem. 1997 Dec 19;272(51):32395-400
9405448
Neurobiol Dis. 2006 Nov;24(2):357-66
16959492
Am J Physiol Regul Integr Comp Physiol. 2008 Dec;295(6):R1973-81
18832080
Childs Nerv Syst. 2003 Jan;19(1):19-22
12541081
J Neurosci. 2006 Jan 25;26(4):1269-74
16436614
Acta Neuropathol. 2001 Mar;101(3):271-6
11307627
J Neurosci. 2006 Sep 13;26(37):9471-81
16971531
J Neurotrauma. 2009 Sep;26(9):1557-66
19203226
Anat Embryol (Berl). 2004 Mar;207(6):503-12
14770308
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9855-60
15210945
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4044-9
11259643
JAMA. 2005 Jul 20;294(3):318-25
16030276
Pediatr Res. 1999 Nov;46(5):543-7
10541316
Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6185-90
18413601
J Neuropathol Exp Neurol. 2002 Feb;61(2):197-211
11853021
Int J Dev Neurosci. 2008 Feb;26(1):103-11
17936539
Behav Brain Res. 2004 Aug 12;153(1):77-86
15219709
Neurosci Lett. 2004 Jan 30;355(3):165-8
14732457
BJOG. 2005 Mar;112 Suppl 1:10-5
15715587
Eur J Neurol. 2008 Feb;15(2):140-9
18093155
Pediatr Res. 2005 Jun;57(6):865-72
15774844
J Cereb Blood Flow Metab. 1999 Jun;19(6):643-51
10366194